PTC Therapeutics, Inc.
PTCT
Classificação em ações
#3334
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Preço da ação
$62.83
Valor de mercado
$5.24B
Variação (1 dia)
2.11%
Variação (1 ano)
-8.09%
País
US
Negociar PTC Therapeutics, Inc. (PTCT)
Categoria
Healthcare
Rácio P/E de PTC Therapeutics, Inc. (PTCT)
Rácio P/E em October 2026 TTM: -121.78
De acordo com os últimos relatórios financeiros e o preço das ações da PTC Therapeutics, Inc., o rácio P/E atual (TTM) é -121.78. No final de 2023, a empresa tinha um P/E de -3.29.
Histórico do rácio P/E da PTC Therapeutics, Inc. de 2011 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | -121.78 | 1,175.14% |
| 2024 | -9.55 | 190.07% |
| 2023 | -3.29 | -32.79% |
| 2022 | -4.90 | -8.58% |
| 2021 | -5.36 | -41.75% |
| 2020 | -9.20 | -18.16% |
| 2019 | -11.24 | -9.95% |
| 2018 | -12.48 | 51.14% |
| 2017 | -8.26 | 215.93% |
| 2016 | -2.61 | -59.10% |
| 2015 | -6.39 | -63.34% |
| 2014 | -17.43 | 313.05% |
| 2013 | -4.22 | -52.68% |
| 2012 | -8.92 | -217.80% |
| 2011 | 7.57 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 28.78 | -123.64% |
US
|
|
| -28.36 | -76.71% |
US
|
|
| -24.57 | -79.83% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -124.91% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.